(Q37777534)

23 August 2017

1 reference

title

Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy (English)

1 reference

23 August 2017

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy (English)

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

16 June 2024

author name string

John J. Wright

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682705

16 June 2024

language of work or name

English

0 references

publication date

3 August 2010

1 reference

full work available at URL

23 August 2017

https://aacr.figshare.com/articles/journal_contribution/Supplementary_Data_from_Combination_Therapy_of_Bortezomib_with_Novel_Targeted_Agents_An_Emerging_Treatment_Strategy/22443057/1/files/39894003.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682705

http://clincancerres.aacrjournals.org/cgi/content/abstract/16/16/4094

16 June 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682705

https://aacrjournals.org/clincancerres/article-pdf/16/16/4094/1991387/4094.pdf

16 June 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

16 June 2024

published in

Clinical Cancer Research

1 reference

23 August 2017

volume

16

1 reference

23 August 2017

issue

16

1 reference

23 August 2017

page(s)

4094-4104

1 reference

Approval summary for bortezomib for injection in the treatment of multiple myeloma

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Strategies for optimizing combinations of molecularly targeted anticancer agents

16 June 2024

2

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

16 June 2024

3

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Bortezomib for the treatment of mantle cell lymphoma

16 June 2024

4

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Development of the proteasome inhibitor Velcade (Bortezomib).

16 June 2024

5

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

16 June 2024

6

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

16 June 2024

7

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

16 June 2024

9

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.

16 June 2024

10

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Histone deacetylase inhibitors in cancer therapy

16 June 2024

11

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

16 June 2024

12

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Protein deacetylases: enzymes with functional diversity as novel therapeutic targets

16 June 2024

13

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

16 June 2024

14

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

16 June 2024

15

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species

16 June 2024

16

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells

16 June 2024

17

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

16 June 2024

19

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

16 June 2024

20

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

16 June 2024

21

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

16 June 2024

22

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib

16 June 2024

23

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

16 June 2024

25

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

16 June 2024

30

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process

16 June 2024

31

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Sorafenib for the treatment of advanced renal cell carcinoma

16 June 2024

37

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Sorafenib for the treatment of unresectable hepatocellular carcinoma

16 June 2024

38

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

16 June 2024

39

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

16 June 2024

41

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

16 June 2024

42

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

16 June 2024

46

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.

16 June 2024

47

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.

16 June 2024

48

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

16 June 2024

49

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

16 June 2024

51

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

16 June 2024

52

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.

16 June 2024

53

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

16 June 2024

55

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

16 June 2024

57

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma

16 June 2024

59

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

16 June 2024

60

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia

16 June 2024

63

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

16 June 2024

65

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

16 June 2024

66

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

16 June 2024

67

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Antimyeloma activity of heat shock protein-90 inhibition.

16 June 2024

69

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

16 June 2024

71

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

16 June 2024

74

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

16 June 2024

76

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak

16 June 2024

77

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.

16 June 2024

78

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

16 June 2024

80

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

16 June 2024

81

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

16 June 2024

82

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.

16 June 2024

83

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

16 June 2024

84

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies

16 June 2024

86

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells

16 June 2024

88

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.

16 June 2024

89

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner

16 June 2024

90

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

The current status and future of multiple myeloma in the clinic

16 June 2024

91

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Novel therapies in the treatment of multiple myeloma

16 June 2024

92

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

16 June 2024

93

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

16 June 2024

94

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

16 June 2024

95

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

16 June 2024

96

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

16 June 2024

97

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

16 June 2024

98

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

16 June 2024

99

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

16 June 2024

100

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-09-2882

16 June 2024

Identifiers

1 reference

23 August 2017

1 reference